The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias
Abstract
In the absence of adequate aspirate films and touch imprints, distinction of chronic myelomonocytic leukaemia (CMML) from acute myeloid leukaemia with monocytic differentiation (Mo-AML) may be difficult solely on the basis of bone marrow biopsy morphological features. The aim of this study was to evaluate the diagnostic utility of a novel immunohistochemical panel for the diagnosis of acute and chronic myelomonocytic leukaemias in bone marrow biopsies. Immunohistochemical labelling for CD14, CD123, CD33, myeloperoxidase (MPO) and CD68R was assessed in 49 myeloid neoplasms with monocytic differentiation (24 CMMLs and 25 Mo-AMLs) and compared with that of 15 non-monocytic acute myeloid leukaemias (NM-AMLs) and 17 non-neoplastic controls. More than 20% CD14 immunohistochemistry (IHC)+ cells were seen only in Mo-AMLs and CMMLs, although Mo-AMLs showed wide variability and overlapped with other categories. More than 20% CD68R IHC+ cells had the highest sensitivity and specificity for Mo-AML. Discrepant MPO-/CD33+ expression was specific for Mo-AML but insensitive. A subset of blasts in Mo-AMLs and NM-AMLs were weakly CD123+. A significantly increased number of CD14+ cells raises the possibility of a myelomonocytic neoplasm but does ...Continue Reading
References
Flow cytometric analysis of different CD14 epitopes can help identify immature monocytic populations
Citations
Related Concepts
Related Feeds
AML: Role of LSD1 by CRISPR (Keystone)
Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.
Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.